The sub-study is a modest positive for the TAMP platform's scientific credibility but does not derisk the binary Phase III outcome. Monitor for full enrollment announcement (June 2026) and final data (mid-late 2027).
Price Chart
Executive Summary
RenovoRx announced the publication of a PK/PD sub-study from its Phase III TIGeR-PaC trial at ASCO 2026, showing that intra-arterial gemcitabine via RenovoCath reduces systemic drug exposure and increases metabolite levels correlated with CA 19-9 reduction. The company also reported $1.1M in RenovoCath sales for 2025 and $563K in Q1 2026, with full trial enrollment expected in June 2026 and final data in mid-late 2027. The sub-study is a modest positive signal for the TAMP platform but does not change the binary risk of the Phase III readout.
Key Financial Metrics
Key Facts
- PK/PD sub-study of Phase III TIGeR-PaC trial published online for ASCO 2026 (May 29-June 2).
- IAG (intra-arterial gemcitabine via RenovoCath) showed reduced systemic gemcitabine levels and increased inactive metabolite, correlated with CA 19-9 reduction in 16 patients.
- RenovoCath sales: $1.1M in FY2025, $563K in Q1 2026.
- Full TIGeR-PaC enrollment expected June 2026; final data readout mid-late 2027.
- IAG has Orphan Drug Designation for pancreatic and bile duct cancer.
Financial Impact
Commercial revenue of $1.1M in 2025 and $563K in Q1 2026; no financial impact from sub-study itself.
Risk Factors
- Phase III TIGeR-PaC trial may fail to meet endpoints, rendering the sub-study moot.
- Low commercial revenue ($1.1M) and cash burn risk; company may need additional financing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3301084 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | Press Release | $1.27 | awaiting T+60 | — | $1.31 (+3.15%) |
Jul 29, 2026 12w ago | Press Release | $0.8981 $1.27 | ▲ +41.41% | ▲ +36.68% | $1.31 (+45.86%) |
Jul 2, 2026 16w ago | 8-K | $0.9201 $1.68 | ▼ −82.59% | ▼ −79.58% | $1.31 (−42.38%) |
May 26, 2026 21w ago | Press Release | $0.9160 $1.32 | ▲ +43.56% | ▲ +40.83% | $1.31 (+43.01%) |
May 19, 2026 22w ago | Press Release | $0.8060 $1.26 | ▲ +56.33% | ▲ +50.04% | $1.31 (+62.53%) |
May 15, 2026 23w ago | 10-K/A | $0.7830 $1.12 | ▲ +43.04% | ▲ +38.19% | $1.31 (+67.31%) |
May 14, 2026 23w ago | 8-K | $0.8200 $1.15 | ▲ +40.24% | ▲ +35.73% | $1.31 (+59.76%) |
Apr 29, 2026 25w ago | Press Release | $0.8310 $0.8653 | ▲ +4.13% | ▲ +0.02% | $1.31 (+57.64%) |
Apr 28, 2026 26w ago | EFFECT | $0.8400 $0.8545 | ▲ +1.73% | ▼ −2.26% | $1.31 (+55.95%) |
Apr 16, 2026 27w ago | S-3 | $1.00 $0.8500 | ▼ −15.00% | ▼ −21.14% | $1.31 (+31.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers